NUCLEOTIDE DERIVATIVES WHICH ARE HCV INHIBITORS FOR USE IN THE TREATMENT OF HEPATITIS C
Use of a compound represented by formula (1A), or a pharmaceutically acceptable salt thereof, in the therapy of HCV in a mammal or human, wherein the compound of formula 1A is administered in combination with a further HCV antiviral selected from: a) asunaprevir, daclatasvir and/or beclabuvir; or b)...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | PINHO, Pedro KALAYANOV, Gennadiy TARGETT-ADAMS, Paul TORSSELL, Staffan |
| description | Use of a compound represented by formula (1A), or a pharmaceutically acceptable salt thereof, in the therapy of HCV in a mammal or human, wherein the compound of formula 1A is administered in combination with a further HCV antiviral selected from: a) asunaprevir, daclatasvir and/or beclabuvir; or b) simeprevir and/or JNJ56914845; or c) an HCV protease inhibitor selected from paritaprevir or ABT493, and an NS5A inhibitor selected from ombitasvir or ABT-530; or d) alisporavir; or e) EDP-239; or f) odalasvir and/or sovaprevir; or g) grazoprevir and/or elbasvir.
L'invention concerne l'utilisation d'un composé représenté par la formule (1A), ou un sel pharmaceutiquement acceptable de ce dernier, dans le traitement contre le VHC chez le mammifère ou l'homme, le composé de formule 1A étant administré en association avec un autre antiviral contre le VHC sélectionné entre : a) l'asunaprevir, le daclatasvir et/ou le beclabuvir ; ou b) le simeprevir et/ou le JNJ56914845 ; ou c) un inhibiteur de protéase du VHC sélectionné entre le paritaprevir ou l'ABT493, et un inhibiteur de NS5A sélectionné entre l'ombitasvir ou l'ABT-530 ; ou d) l'alisporavir ; ou e) l'EDP-239 ; ou f) l'odalasvir et/ou le sovaprevir ; ou g) le grazoprevir et/ou l'elbasvir. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2016140615A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2016140615A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2016140615A13</originalsourceid><addsrcrecordid>eNqNi8sKwjAQAHPxIOo_LHgWGh-9x3TDLmgiybY5liLxJFqo_489-AGeBoaZpcq-tRcMwg1Cg5E7I9xhgkxsCUxEINsBe-IzS4gJXIjQJpwVCCFIRCNX9ALBAeFt3oUT2LVaPIbnVDY_rtTWoVjalfHdl2kc7uVVPn0O-0rX-ljV-mT04b_qC29xMZ4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>NUCLEOTIDE DERIVATIVES WHICH ARE HCV INHIBITORS FOR USE IN THE TREATMENT OF HEPATITIS C</title><source>esp@cenet</source><creator>PINHO, Pedro ; KALAYANOV, Gennadiy ; TARGETT-ADAMS, Paul ; TORSSELL, Staffan</creator><creatorcontrib>PINHO, Pedro ; KALAYANOV, Gennadiy ; TARGETT-ADAMS, Paul ; TORSSELL, Staffan</creatorcontrib><description>Use of a compound represented by formula (1A), or a pharmaceutically acceptable salt thereof, in the therapy of HCV in a mammal or human, wherein the compound of formula 1A is administered in combination with a further HCV antiviral selected from: a) asunaprevir, daclatasvir and/or beclabuvir; or b) simeprevir and/or JNJ56914845; or c) an HCV protease inhibitor selected from paritaprevir or ABT493, and an NS5A inhibitor selected from ombitasvir or ABT-530; or d) alisporavir; or e) EDP-239; or f) odalasvir and/or sovaprevir; or g) grazoprevir and/or elbasvir.
L'invention concerne l'utilisation d'un composé représenté par la formule (1A), ou un sel pharmaceutiquement acceptable de ce dernier, dans le traitement contre le VHC chez le mammifère ou l'homme, le composé de formule 1A étant administré en association avec un autre antiviral contre le VHC sélectionné entre : a) l'asunaprevir, le daclatasvir et/ou le beclabuvir ; ou b) le simeprevir et/ou le JNJ56914845 ; ou c) un inhibiteur de protéase du VHC sélectionné entre le paritaprevir ou l'ABT493, et un inhibiteur de NS5A sélectionné entre l'ombitasvir ou l'ABT-530 ; ou d) l'alisporavir ; ou e) l'EDP-239 ; ou f) l'odalasvir et/ou le sovaprevir ; ou g) le grazoprevir et/ou l'elbasvir.</description><language>eng ; fre</language><subject>CHEMISTRY ; DERIVATIVES THEREOF ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; NUCLEIC ACIDS ; NUCLEOSIDES ; NUCLEOTIDES ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SUGARS</subject><creationdate>2016</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160909&DB=EPODOC&CC=WO&NR=2016140615A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25547,76298</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160909&DB=EPODOC&CC=WO&NR=2016140615A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>PINHO, Pedro</creatorcontrib><creatorcontrib>KALAYANOV, Gennadiy</creatorcontrib><creatorcontrib>TARGETT-ADAMS, Paul</creatorcontrib><creatorcontrib>TORSSELL, Staffan</creatorcontrib><title>NUCLEOTIDE DERIVATIVES WHICH ARE HCV INHIBITORS FOR USE IN THE TREATMENT OF HEPATITIS C</title><description>Use of a compound represented by formula (1A), or a pharmaceutically acceptable salt thereof, in the therapy of HCV in a mammal or human, wherein the compound of formula 1A is administered in combination with a further HCV antiviral selected from: a) asunaprevir, daclatasvir and/or beclabuvir; or b) simeprevir and/or JNJ56914845; or c) an HCV protease inhibitor selected from paritaprevir or ABT493, and an NS5A inhibitor selected from ombitasvir or ABT-530; or d) alisporavir; or e) EDP-239; or f) odalasvir and/or sovaprevir; or g) grazoprevir and/or elbasvir.
L'invention concerne l'utilisation d'un composé représenté par la formule (1A), ou un sel pharmaceutiquement acceptable de ce dernier, dans le traitement contre le VHC chez le mammifère ou l'homme, le composé de formule 1A étant administré en association avec un autre antiviral contre le VHC sélectionné entre : a) l'asunaprevir, le daclatasvir et/ou le beclabuvir ; ou b) le simeprevir et/ou le JNJ56914845 ; ou c) un inhibiteur de protéase du VHC sélectionné entre le paritaprevir ou l'ABT493, et un inhibiteur de NS5A sélectionné entre l'ombitasvir ou l'ABT-530 ; ou d) l'alisporavir ; ou e) l'EDP-239 ; ou f) l'odalasvir et/ou le sovaprevir ; ou g) le grazoprevir et/ou l'elbasvir.</description><subject>CHEMISTRY</subject><subject>DERIVATIVES THEREOF</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>NUCLEIC ACIDS</subject><subject>NUCLEOSIDES</subject><subject>NUCLEOTIDES</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SUGARS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2016</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNi8sKwjAQAHPxIOo_LHgWGh-9x3TDLmgiybY5liLxJFqo_489-AGeBoaZpcq-tRcMwg1Cg5E7I9xhgkxsCUxEINsBe-IzS4gJXIjQJpwVCCFIRCNX9ALBAeFt3oUT2LVaPIbnVDY_rtTWoVjalfHdl2kc7uVVPn0O-0rX-ljV-mT04b_qC29xMZ4</recordid><startdate>20160909</startdate><enddate>20160909</enddate><creator>PINHO, Pedro</creator><creator>KALAYANOV, Gennadiy</creator><creator>TARGETT-ADAMS, Paul</creator><creator>TORSSELL, Staffan</creator><scope>EVB</scope></search><sort><creationdate>20160909</creationdate><title>NUCLEOTIDE DERIVATIVES WHICH ARE HCV INHIBITORS FOR USE IN THE TREATMENT OF HEPATITIS C</title><author>PINHO, Pedro ; KALAYANOV, Gennadiy ; TARGETT-ADAMS, Paul ; TORSSELL, Staffan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2016140615A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2016</creationdate><topic>CHEMISTRY</topic><topic>DERIVATIVES THEREOF</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>NUCLEIC ACIDS</topic><topic>NUCLEOSIDES</topic><topic>NUCLEOTIDES</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SUGARS</topic><toplevel>online_resources</toplevel><creatorcontrib>PINHO, Pedro</creatorcontrib><creatorcontrib>KALAYANOV, Gennadiy</creatorcontrib><creatorcontrib>TARGETT-ADAMS, Paul</creatorcontrib><creatorcontrib>TORSSELL, Staffan</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>PINHO, Pedro</au><au>KALAYANOV, Gennadiy</au><au>TARGETT-ADAMS, Paul</au><au>TORSSELL, Staffan</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>NUCLEOTIDE DERIVATIVES WHICH ARE HCV INHIBITORS FOR USE IN THE TREATMENT OF HEPATITIS C</title><date>2016-09-09</date><risdate>2016</risdate><abstract>Use of a compound represented by formula (1A), or a pharmaceutically acceptable salt thereof, in the therapy of HCV in a mammal or human, wherein the compound of formula 1A is administered in combination with a further HCV antiviral selected from: a) asunaprevir, daclatasvir and/or beclabuvir; or b) simeprevir and/or JNJ56914845; or c) an HCV protease inhibitor selected from paritaprevir or ABT493, and an NS5A inhibitor selected from ombitasvir or ABT-530; or d) alisporavir; or e) EDP-239; or f) odalasvir and/or sovaprevir; or g) grazoprevir and/or elbasvir.
L'invention concerne l'utilisation d'un composé représenté par la formule (1A), ou un sel pharmaceutiquement acceptable de ce dernier, dans le traitement contre le VHC chez le mammifère ou l'homme, le composé de formule 1A étant administré en association avec un autre antiviral contre le VHC sélectionné entre : a) l'asunaprevir, le daclatasvir et/ou le beclabuvir ; ou b) le simeprevir et/ou le JNJ56914845 ; ou c) un inhibiteur de protéase du VHC sélectionné entre le paritaprevir ou l'ABT493, et un inhibiteur de NS5A sélectionné entre l'ombitasvir ou l'ABT-530 ; ou d) l'alisporavir ; ou e) l'EDP-239 ; ou f) l'odalasvir et/ou le sovaprevir ; ou g) le grazoprevir et/ou l'elbasvir.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2016140615A1 |
| source | esp@cenet |
| subjects | CHEMISTRY DERIVATIVES THEREOF HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY NUCLEIC ACIDS NUCLEOSIDES NUCLEOTIDES ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SUGARS |
| title | NUCLEOTIDE DERIVATIVES WHICH ARE HCV INHIBITORS FOR USE IN THE TREATMENT OF HEPATITIS C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T06%3A54%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=PINHO,%20Pedro&rft.date=2016-09-09&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2016140615A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |